Mauro Giulio Papotti

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3694674/publications.pdf

Version: 2024-02-01

303 papers 20,864 citations

75 h-index 131 g-index

309 all docs

309 docs citations

times ranked

309

16109 citing authors

#	Article	IF	Citations
1	The 2021 WHO Classification of Tumors of the Thymus and Mediastinum: What Is New in Thymic Epithelial, Germ Cell, and Mesenchymal Tumors?. Journal of Thoracic Oncology, 2022, 17, 200-213.	0.5	124
2	Malignant pleural mesothelioma: Germline variants in DNA repair genes may steer tailored treatment. European Journal of Cancer, 2022, 163, 44-54.	1.3	14
3	SKP2 drives the sensitivity to neddylation inhibitors and cisplatin in malignant pleural mesothelioma. Journal of Experimental and Clinical Cancer Research, 2022, 41, 75.	3.5	7
4	Spectrum of Kidney Injury Following COVID-19 Disease: Renal Biopsy Findings in a Single Italian Pathology Service. Biomolecules, 2022, 12, 298.	1.8	13
5	Development and internal validation of a predictive model for the estimation of pheochromocytoma recurrence risk after radical surgery. European Journal of Endocrinology, 2022, 186, 399-406.	1.9	5
6	Overview of the 2022 WHO Classification of Thyroid Neoplasms. Endocrine Pathology, 2022, 33, 27-63.	5.2	388
7	Renal Involvement in Transthyretin Amyloidosis: The Double Presentation of Transthyretin Amyloidosis Deposition Disease. Nephron, 2022, 146, 481-488.	0.9	4
8	mEPE-score: a comprehensive grading system for predicting pathologic extraprostatic extension of prostate cancer at multiparametric magnetic resonance imaging. European Radiology, 2022, 32, 4942-4953.	2.3	7
9	Overview of the 2022 WHO Classification of Neuroendocrine Neoplasms. Endocrine Pathology, 2022, 33, 115-154.	5.2	227
10	Overview of the 2022 WHO Classification of Adrenal Cortical Tumors. Endocrine Pathology, 2022, 33, 155-196.	5.2	87
11	NSCLC Subtyping in Conventional Cytology: Results of the International Association for the Study of Lung Cancer Cytology Working Group Survey to Determine Specific Cytomorphologic Criteria for Adenocarcinoma and Squamous Cell Carcinoma. Journal of Thoracic Oncology, 2022, 17, 793-805.	0.5	6
12	Micro-RNA-215 and -375 regulate thymidylate synthase protein expression in pleural mesothelioma and mediate epithelial to mesenchymal transition. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2022, , 1.	1.4	1
13	<scp>MicroRNA</scp> profiling predicts positive nodal status in papillary thyroid carcinoma in the preoperative setting. Cancer Cytopathology, 2022, , .	1.4	1
14	Clinical-Pathological Evaluation and Prognostic Analysis of 228 Merkel Cell Carcinomas Focusing on Tumor-Infiltrating Lymphocytes, MCPYV Infection and ALK Expression. Endocrine Pathology, 2022, 33, 289-303.	5.2	2
15	Molecular Subtypes of Extra-pulmonary Neuroendocrine Carcinomas Identified by the Expression of Neuroendocrine Lineage-Specific Transcription Factors. Endocrine Pathology, 2022, 33, 388-399.	5.2	7
16	From SGAP-Model to SGAP-Score: A Simplified Predictive Tool for Post-Surgical Recurrence of Pheochromocytoma. Biomedicines, 2022, 10, 1310.	1.4	3
17	International Histopathology Consensus for Unilateral Primary Aldosteronism. Journal of Clinical Endocrinology and Metabolism, 2021, 106, 42-54.	1.8	127
18	Malignant struma ovarii: next-generation sequencing of six cases revealed Nras, Braf, and Jak3 mutations. Endocrine, 2021, 71, 216-224.	1.1	12

#	Article	IF	CITATIONS
19	Retrospective analysis of the ultrasound features of resected thyroid nodules. Endocrine, 2021, 72, 486-494.	1.1	2
20	Impact of COVIDâ€19 lockdown measures on oncological surgical activity: Analysis of the surgical pathology caseload of a tertiary referral hospital in Northwestern Italy. Journal of Surgical Oncology, 2021, 123, 24-31.	0.8	23
21	Data set for reporting of carcinoma of the adrenal cortex: explanations and recommendations of the guidelines from the International Collaboration on Cancer Reporting. Human Pathology, 2021, 110, 50-61.	1.1	18
22	Clinical implications of lung neuroendocrine neoplasm classification. Expert Review of Anticancer Therapy, 2021, 21, 377-387.	1.1	4
23	Morphologic and molecular classification of lung neuroendocrine neoplasms. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2021, 478, 5-19.	1.4	44
24	Primary lung adenocarcinoma in three adolescent patients affected by bone sarcomas. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2021, 478, 1125-1134.	1.4	1
25	Genomics of High-Grade Neuroendocrine Neoplasms: Well-Differentiated Neuroendocrine Tumor with High-Grade Features (G3 NET) and Neuroendocrine Carcinomas (NEC) of Various Anatomic Sites. Endocrine Pathology, 2021, 32, 192-210.	5.2	41
26	Molecular Pathology of Poorly Differentiated and Anaplastic Thyroid Cancer: What Do Pathologists Need to Know?. Endocrine Pathology, 2021, 32, 63-76.	5.2	55
27	Neuroendocrine neoplasms of the appendix, colon and rectum. Pathologica, 2021, 113, 19-27.	1.3	36
28	Diagnostic Value of Conventional PET Parameters and Radiomic Features Extracted from 18F-FDG-PET/CT for Histologic Subtype Classification and Characterization of Lung Neuroendocrine Neoplasms. Biomedicines, 2021, 9, 281.	1.4	10
29	Radiofrequency Thermal Ablation for a Small Papillary Thyroid Carcinoma in a Patient Unfit for Surgery: A Case Report. Frontiers in Endocrinology, 2021, 12, 566362.	1.5	4
30	Protective Role of the M-Sec–Tunneling Nanotube System in Podocytes. Journal of the American Society of Nephrology: JASN, 2021, 32, 1114-1130.	3.0	12
31	Intron 4–5 hTERT DNA Hypermethylation in Merkel Cell Carcinoma: Frequency, Association with Other Clinico-pathological Features and Prognostic Relevance. Endocrine Pathology, 2021, 32, 385-395.	5.2	4
32	The International Association for the Study of Lung Cancer Global Survey on Programmed Death-Ligand 1 Testing for NSCLC. Journal of Thoracic Oncology, 2021, 16, 686-696.	0.5	13
33	Pathological Characterization of Tumor Immune Microenvironment (TIME) in Malignant Pleural Mesothelioma. Cancers, 2021, 13, 2564.	1.7	16
34	SMARCA2 Deficiency While Preserving SMARCA4 and SMARCB1 in Lung Neuroendocrine Carcinomas. Journal of Thoracic Oncology, 2021, 16, e32-e35.	0.5	2
35	Predictor Analysis in Radiofrequency Ablation of Benign Thyroid Nodules: A Single Center Experience. Frontiers in Endocrinology, 2021, 12, 638880.	1.5	11
36	Evaluation of the Preclinical Efficacy of Lurbinectedin in Malignant Pleural Mesothelioma. Cancers, 2021, 13, 2332.	1.7	4

#	Article	IF	Citations
37	A hybrid deep learning approach for gland segmentation in prostate histopathological images. Artificial Intelligence in Medicine, 2021, 115, 102076.	3.8	31
38	Placenta histopathology in SARS-CoV-2 infection: analysis of a consecutive series and comparison with control cohorts. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2021, 479, 715-728.	1.4	28
39	Differential Expression Profiles of Cell-to-Matrix-Related Molecules in Adrenal Cortical Tumors: Diagnostic and Prognostic Implications. Journal of Personalized Medicine, 2021, 11, 378.	1.1	3
40	INSM1 Expression in Breast Neoplasms with Neuroedocrine Features. Endocrine Pathology, 2021, 32, 452-460.	5 . 2	12
41	Adrenal Rests in the Uro-genital Tract of an Adult Population. Endocrine Pathology, 2021, 32, 375-384.	5.2	9
42	Caveolin-1 expression predicts favourable outcome and correlates with PDGFRA mutations in gastrointestinal stromal tumours (GISTs). Journal of Clinical Pathology, 2021, , jclinpath-2021-207595.	1.0	1
43	Automated assessment of glomerulosclerosis and tubular atrophy using deep learning. Computerized Medical Imaging and Graphics, 2021, 90, 101930.	3.5	22
44	DNA Methylation Profiling Discriminates between Malignant Pleural Mesothelioma and Neoplastic or Reactive Histologic Mimics. Journal of Molecular Diagnostics, 2021, 23, 834-846.	1.2	7
45	Pituitary metastases from neuroendocrine neoplasms: case report and narrative review. Pituitary, 2021, 24, 828-837.	1.6	6
46	Real-World Data on NGS Diagnostics: a survey from the Italian Society of Pathology (SIAPeC) NGS Network. Pathologica, 2021, 113, 262-271.	1.3	13
47	Automated Analysis of Proliferating Cells Spatial Organisation Predicts Prognosis in Lung Neuroendocrine Neoplasms. Cancers, 2021, 13, 4875.	1.7	7
48	Recent advances and current controversies in lung neuroendocrine neoplasms✰. Seminars in Diagnostic Pathology, 2021, 38, 90-97.	1.0	7
49	Caveolin-1 in Kidney Chronic Antibody-Mediated Rejection: An Integrated Immunohistochemical and Transcriptomic Analysis Based on the Banff Human Organ Transplant (B-HOT) Gene Panel. Biomedicines, 2021, 9, 1318.	1.4	7
50	A Subset of Large Cell Neuroendocrine Carcinomas in the Gastroenteropancreatic Tract May Evolve from Pre-existing Well-Differentiated Neuroendocrine Tumors. Endocrine Pathology, 2021, 32, 396-407.	5.2	16
51	Amyloid-Rich Pancreatic Neuroendocrine Tumors: a Potential Diagnostic Pitfall in Endoscopic Ultrasound–Guided Fine Needle Aspiration Cytology (EUS-FNAC). Endocrine Pathology, 2021, 32, 318-325.	5.2	3
52	Reply to: Oncologic thoracic surgery during the second wave of COVIDâ€19 pandemic: How to be ready for the storm. Journal of Surgical Oncology, 2021, 123, 1169-1169.	0.8	0
53	The Adverse Impact of the COVID-19 Pandemic on Abdominal Emergencies: A Retrospective Clinico-Pathological Analysis. Journal of Clinical Medicine, 2021, 10, 5254.	1.0	7
54	Anti-CD37 Alpha-Amanitin Conjugated Antibodies As Therapeutic Weapons for Richter's Syndrome. Blood, 2021, 138, 791-791.	0.6	4

#	Article	IF	CITATIONS
55	Small-Cell Carcinoma of the Lung: What We Learned about It?. Acta Cytologica, 2021, , 1-12.	0.7	3
56	Role of Immunocytochemistry in the Cytological Diagnosis of Pulmonary Tumors. Acta Cytologica, 2020, 64, 16-29.	0.7	22
57	Predictors of recurrence of pheochromocytoma and paraganglioma: a multicenter study in Piedmont, Italy. Hypertension Research, 2020, 43, 500-510.	1.5	26
58	The Diagnosis of Hyalinizing Trabecular Tumor: A Difficult and Controversial Thyroid Entity. Head and Neck Pathology, 2020, 14, 778-784.	1.3	17
59	Multiple Assays to Determine Methylguanine-Methyltransferase Status in Lung Carcinoids and Correlation with Clinical and Pathological Features. Neuroendocrinology, 2020, 110, 1-9.	1.2	2
60	PD-L1 Testing for Lung Cancer in 2019: Perspective From the IASLC Pathology Committee. Journal of Thoracic Oncology, 2020, 15, 499-519.	0.5	203
61	Exploring the Prognostic Role of Ki67 Proliferative Index in Merkel Cell Carcinoma of the Skin: Clinico-Pathologic Analysis of 84 Cases and Review of the Literature. Endocrine Pathology, 2020, 31, 392-400.	5.2	10
62	Fully automated quantitative assessment of hepatic steatosis in liver transplants. Computers in Biology and Medicine, 2020, 123, 103836.	3.9	18
63	The Oncocytic Variant of Poorly Differentiated Thyroid Carcinoma Shows a Specific Immune-Related Gene Expression Profile. Journal of Clinical Endocrinology and Metabolism, 2020, 105, e4577-e4592.	1.8	8
64	Karpinski Score under Digital Investigation: A Fully Automated Segmentation Algorithm to Identify Vascular and Stromal Injury of Donors' Kidneys. Electronics (Switzerland), 2020, 9, 1644.	1.8	12
65	Prognostic role of PD-L1 and immune-related gene expression profiles in giant cell tumors of bone. Cancer Immunology, Immunotherapy, 2020, 69, 1905-1916.	2.0	6
66	Oncogenic properties and signaling basis of the PAX8â€GLIS3 fusion gene. International Journal of Cancer, 2020, 147, 2253-2264.	2.3	10
67	The Promises and Challenges of Tumor Mutation Burden as an Immunotherapy Biomarker: A Perspective from the International Association for the Study of Lung Cancer Pathology Committee. Journal of Thoracic Oncology, 2020, 15, 1409-1424.	0.5	182
68	A Grading System for Invasive Pulmonary Adenocarcinoma: A Proposal From the International Association for the Study of Lung Cancer Pathology Committee. Journal of Thoracic Oncology, 2020, 15, 1599-1610.	0.5	234
69	IASLC Multidisciplinary Recommendations for Pathologic Assessment of Lung Cancer Resection Specimens After Neoadjuvant Therapy. Journal of Thoracic Oncology, 2020, 15, 709-740.	0.5	205
70	NTRK Fusions in Central Nervous System Tumors: A Rare, but Worthy Target. International Journal of Molecular Sciences, 2020, 21, 753.	1.8	62
71	Immunization against ROS1 by DNA Electroporation Impairs K-Ras-Driven Lung Adenocarcinomas. Vaccines, 2020, 8, 166.	2.1	1
72	Noninvasive Follicular Thyroid Neoplasm with Papillary-Like Nuclear Features: From Echography to Genetic Profile. Tohoku Journal of Experimental Medicine, 2020, 252, 209-218.	0.5	2

#	Article	IF	CITATIONS
73	ACTH-producing tumorlets and carcinoids of the lung: clinico-pathologic study of 63 cases and review of the literature. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2019, 475, 587-597.	1.4	22
74	PAX8–GLIS3 gene fusion is a pathognomonic genetic alteration of hyalinizing trabecular tumors of the thyroid. Modern Pathology, 2019, 32, 1734-1743.	2.9	38
75	DNA methylation in repeat negative prostate biopsies as a marker of missed prostate cancer. Clinical Epigenetics, 2019, 11, 152.	1.8	7
76	Antagonists of growth hormone-releasing hormone (GHRH) inhibit the growth of human malignant pleural mesothelioma. Proceedings of the National Academy of Sciences of the United States of America, 2019, 116, 2226-2231.	3.3	29
77	Potential Diagnostic and Prognostic Role of Microenvironment in Malignant Pleural Mesothelioma. Journal of Thoracic Oncology, 2019, 14, 1458-1471.	0.5	41
78	Spread through air spaces (STAS) is a predictor of poor outcome in atypical carcinoids of the lung. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2019, 475, 325-334.	1.4	18
79	Immunocytochemistry for predictive biomarker testing in lung cancer cytology. Cancer Cytopathology, 2019, 127, 325-339.	1.4	78
80	Recent advances in the molecular landscape of lung neuroendocrine tumors. Expert Review of Molecular Diagnostics, 2019, 19, 281-297.	1.5	38
81	PD-1 (PDCD1) promoter methylation in Merkel cell carcinoma: prognostic relevance and relationship with clinico-pathological parameters. Modern Pathology, 2019, 32, 1359-1372.	2.9	19
82	Best Practices Recommendations for Diagnostic Immunohistochemistry in Lung Cancer. Journal of Thoracic Oncology, 2019, 14, 377-407.	0.5	212
83	Prostate cancer detection with biparametric magnetic resonance imaging (bpMRI) by readers with different experience: performance and comparison with multiparametric (mpMRI). Abdominal Radiology, 2019, 44, 1883-1893.	1.0	80
84	Proton pump inhibitors promote the growth of androgen-sensitive prostate cancer cells through ErbB2, ERK1/2, Pl3K/Akt, GSK-3β signaling and inhibition of cellular prostatic acid phosphatase. Cancer Letters, 2019, 449, 252-262.	3.2	19
85	Anticoagulation in patients with concomitant lupus nephritis and thrombotic microangiopathy: a multicentre cohort study. Annals of the Rheumatic Diseases, 2019, 78, 1004-1006.	0.5	23
86	Primary Thymic Signet Ring Cell Adenocarcinoma: A Currently Unrecognized Variant. International Journal of Surgical Pathology, 2019, 27, 315-321.	0.4	4
87	Prognostic Characterization of Higher-Grade Meningiomas: A Histopathological Score to Predict Progression and Outcome. Journal of Neuropathology and Experimental Neurology, 2019, 78, 248-256.	0.9	10
88	Eccrine spiradenoma of the nipple: Case report, differential diagnosis and literature review. Histology and Histopathology, 2019, 34, 909-915.	0.5	0
89	Immunohistochemical Biomarkers of Gastrointestinal, Pancreatic, Pulmonary, and Thymic Neuroendocrine Neoplasms. Endocrine Pathology, 2018, 29, 150-168.	5.2	89
90	The utility of blood neuroendocrine gene transcript measurement in the diagnosis of bronchopulmonary neuroendocrine tumours and as a tool to evaluate surgical resection and disease progressionâ€. European Journal of Cardio-thoracic Surgery, 2018, 53, 631-639.	0.6	35

#	Article	IF	CITATIONS
91	High interlaboratory and interobserver agreement of somatostatin receptor immunohistochemical determination and correlation with response to somatostatin analogs. Human Pathology, 2018, 72, 144-152.	1.1	32
92	Immunohistochemical Biomarkers of Adrenal Cortical Neoplasms. Endocrine Pathology, 2018, 29, 137-149.	5.2	45
93	Ki67 proliferative index of the neuroendocrine component drives MANEC prognosis. Endocrine-Related Cancer, 2018, 25, 583-593.	1.6	77
94	Molecular and Histopathological Characterization of the Tumor Immune Microenvironment in Advanced Stage of Malignant Pleural Mesothelioma. Journal of Thoracic Oncology, 2018, 13, 124-133.	0.5	52
95	Molecular alterations of neuroendocrine tumours of the lung. Histopathology, 2018, 72, 142-152.	1.6	37
96	Eighth Edition of the UICC Classification of Malignant Tumours: an overview of the changes in the pathological TNM classification criteria—What has changed and why?. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2018, 472, 519-531.	1.4	106
97	Pathologic Grading of Malignant Pleural Mesothelioma: An Evidence-Based Proposal. Journal of Thoracic Oncology, 2018, 13, 1750-1761.	0.5	27
98	ALK expression favorably impacts the prognosis of NRAS‑mutated metastatic melanomas. Oncology Letters, 2018, 16, 7091-7096.	0.8	1
99	CXCL12 expression is a bona fide predictor of recurrence in lung neuroendocrine tumours; a multicentric study with emphasis on atypical carcinoidsÂ- a short report. Cellular Oncology (Dordrecht), 2018, 41, 687-691.	2.1	2
100	Detection of Angiotensin II type lâ€receptor antibodies in transplant glomerulopathy. Clinical Transplantation, 2018, 32, e13407.	0.8	1
101	Pathological prognostic markers in central nervous system solitary fibrous tumour/hemangiopericytoma: Evidence from a small series. PLoS ONE, 2018, 13, e0203570.	1.1	11
102	Safe transportation of formalin-fixed liquid-free pathology specimens. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2018, 473, 105-113.	1.4	8
103	Noninvasive Follicular Thyroid Neoplasm With Papillary-Like Nuclear Features (NIFTP): Achieving Better Agreement By Refining Diagnostic Criteria. Clinics, 2018, 73, e576.	0.6	40
104	High miR-100 expression is associated with aggressive features and modulates TORC1 complex activation in lung carcinoids. Oncotarget, 2018, 9, 27535-27546.	0.8	5
105	TREM-1 expression in HPV related oropharyngeal squamous cell carcinoma (OP-SCC) Journal of Clinical Oncology, 2018, 36, e18037-e18037.	0.8	0
106	Precision medicine in age-specific non-small-cell-lung-cancer patients: Integrating biomolecular results into clinical practice—A new approach to improve personalized translational research. Lung Cancer, 2017, 107, 84-90.	0.9	30
107	Tissue Expression and Pharmacological In Vitro Analyses of mTOR and SSTR Pathways in Adrenocortical Carcinoma. Endocrine Pathology, 2017, 28, 95-102.	5.2	15
108	Caveolin 1 expression favors tumor growth and is associated with poor survival in primary lung adenocarcinomas. Tumor Biology, 2017, 39, 101042831769431.	0.8	10

#	Article	IF	Citations
109	Images in Endocrine Pathology: Unique Composite Adrenal Adenomatoid Tumor, Ganglioneuroma, Myelolipoma, and Cortical Nodular Hyperplasia. Endocrine Pathology, 2017, 28, 276-279.	5.2	3
110	Interpathologist concordance in the histological diagnosis of focal prostatic atrophy lesions, acute and chronic prostatitis, PIN, and prostate cancer. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2017, 470, 711-715.	1.4	12
111	Distinctive pathological and clinical features of lung carcinoids with high proliferation index. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2017, 471, 713-720.	1.4	64
112	Analysis of histological and immunohistochemical patterns of benign and malignant adrenocortical tumors by computerized morphometry. Pathology Research and Practice, 2017, 213, 815-823.	1.0	5
113	The genetic landscape of breast carcinomas with neuroendocrine differentiation. Journal of Pathology, 2017, 241, 405-419.	2.1	52
114	Validation of the prognostic role of the "Helsinki Score―in 225 cases of adrenocortical carcinoma. Human Pathology, 2017, 62, 1-7.	1.1	69
115	Ki-67 labeling index of neuroendocrine tumors of the lung has a high level of correspondence between biopsy samples and surgical specimens when strict counting guidelines are applied. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2017, 470, 153-164.	1.4	67
116	Mitochondrial DNA "common deletion―in post–fine needle aspiration infarcted oncocytic thyroid tumors. Human Pathology, 2017, 69, 23-30.	1.1	4
117	Multicenter Comparison of 22C3 PharmDx (Agilent) and SP263 (Ventana) Assays to Test PD-L1 Expression for NSCLC Patients to Be Treated with Immune Checkpoint Inhibitors. Journal of Thoracic Oncology, 2017, 12, 1654-1663.	0.5	81
118	Management of Progressive Pulmonary Nodules FoundÂduring and outside of CT Lung Cancer Screening Studies. Journal of Thoracic Oncology, 2017, 12, 1755-1765.	0.5	9
119	Assessment of VAV2 Expression Refines Prognostic Prediction in Adrenocortical Carcinoma. Journal of Clinical Endocrinology and Metabolism, 2017, 102, 3491-3498.	1.8	33
120	The Potential of Combined Immunotherapy and Antiangiogenesis for the Synergistic Treatment of Advanced NSCLC. Journal of Thoracic Oncology, 2017, 12, 194-207.	0.5	186
121	Lung neuroendocrine tumors: pathological characteristics. Journal of Thoracic Disease, 2017, 9, \$1442-\$1447.	0.6	29
122	Classification of pulmonary neuroendocrine tumors: new insights. Translational Lung Cancer Research, 2017, 6, 513-529.	1.3	104
123	An International Ki67 Reproducibility Study in Adrenal Cortical Carcinoma. American Journal of Surgical Pathology, 2016, 40, 569-576.	2.1	75
124	Noninvasive follicular thyroid neoplasm with papillaryâ€like nuclear features (NIFTP): A changing paradigm in thyroid surgical pathology and implications for thyroid cytopathology. Cancer Cytopathology, 2016, 124, 616-620.	1.4	105
125	Optimal Ki67 cut-off for luminal breast cancer prognostic evaluation: a large case series study with a long-term follow-up. Breast Cancer Research and Treatment, 2016, 157, 363-371.	1.1	156
126	Cytological features of "noninvasive follicular thyroid neoplasm with papillary-like nuclear features―and their correlation with tumor histology. Human Pathology, 2016, 54, 134-142.	1.1	190

#	Article	IF	Citations
127	Nomenclature Revision for Encapsulated Follicular Variant of Papillary Thyroid Carcinoma. JAMA Oncology, 2016, 2, 1023.	3.4	1,192
128	Mesothelioma families without inheritance of a BAP1 predisposing mutation. Cancer Genetics, 2016, 209, 381-387.	0.2	13
129	BRCA1-Associated Protein 1 (BAP1) Immunohistochemical Expression as a Diagnostic Tool in Malignant Pleural Mesothelioma Classification: A Large Retrospective Study. Journal of Thoracic Oncology, 2016, 11, 2006-2017.	0.5	83
130	Sarcomatoid adrenocortical carcinoma: a comprehensive pathological, immunohistochemical, and targeted next-generation sequencing analysis. Human Pathology, 2016, 58, 113-122.	1.1	25
131	Androgen deprivation modulates gene expression profile along prostate cancer progression. Human Pathology, 2016, 56, 81-88.	1.1	20
132	Management of Patients with Castration-Resistant Prostate Cancer (CRPC): Results of an Italian Survey Using the Delphi Method. Tumori, 2016, 102, 514-520.	0.6	2
133	The story of poorly differentiated thyroid carcinoma: From Langhans' description to the Turin proposal via Juan Rosai. Seminars in Diagnostic Pathology, 2016, 33, 277-283.	1.0	21
134	Retrospective Multicenter Study Investigating the Role of Targeted Next-Generation Sequencing of Selected Cancer Genes in Mucinous Adenocarcinoma of the Lung. Journal of Thoracic Oncology, 2016, 11, 504-515.	0.5	19
135	MET mutations are associated with aggressive and radioresistant brain metastatic non-small-cell lung cancer: Table 1 Neuro-Oncology, 2016, 18, 598-599.	0.6	15
136	Synergistic Activation upon MET and ALK Coamplification Sustains Targeted Therapy in Sarcomatoid Carcinoma, a Deadly Subtype of Lung Cancer. Journal of Thoracic Oncology, 2016, 11, 718-728.	0.5	22
137	Novel active agents in patients with advanced NSCLC without driver mutations who have progressed after first-line chemotherapy. ESMO Open, 2016, 1, e000118.	2.0	6
138	Dasatinib modulates sensitivity to pemetrexed in malignant pleural mesothelioma cell lines. Oncotarget, 2016, 7, 76577-76589.	0.8	13
139	Retrospective study testing next generation sequencing of selected cancer-associated genes in resected prostate cancer. Oncotarget, 2016, 7, 14394-14404.	0.8	23
140	Ki-67 proliferation index but not mitotic thresholds integrates the molecular prognostic stratification of lower grade gliomas. Oncotarget, 2016, 7, 21190-21198.	0.8	24
141	Dissecting Pulmonary Large-Cell Carcinoma by Targeted Next Generation Sequencing of Several Cancer Genes Pushes Genotypic-Phenotypic Correlations to Emerge. Journal of Thoracic Oncology, 2015, 10, 1560-1569.	0.5	26
142	Utilility of flow cytometry as ancillary study to improve the cytologic diagnosis of thyroid lymphomas. Cytometry Part B - Clinical Cytometry, 2015, 88, 320-329.	0.7	22
143	Dissecting morphological and molecular heterogeneity in adrenocortical carcinoma. Turk Patoloji Dergisi, 2015, 31 Suppl 1, 98-104.	0.1	6
144	YKL-40/c-Met Expression in Rectal Cancer Biopsies Predicts Tumor Regression following Neoadjuvant Chemoradiotherapy: A Multi-Institutional Study. PLoS ONE, 2015, 10, e0123759.	1.1	14

#	Article	IF	Citations
145	SDHB/SDHA immunohistochemistry in pheochromocytomas and paragangliomas: a multicenter interobserver variation analysis using virtual microscopy: a Multinational Study of the European Network for the Study of Adrenal Tumors (ENS@T). Modern Pathology, 2015, 28, 807-821.	2.9	176
146	Safety and diagnostic performance of image-guided lung biopsy in the targeted therapy era. Radiologia Medica, 2015, 120, 1024-1030.	4.7	5
147	What clinicians are asking pathologists when dealing with lung neuroendocrine neoplasms?. Seminars in Diagnostic Pathology, 2015, 32, 469-479.	1.0	27
148	Major Prognostic Role of Ki67 in Localized Adrenocortical Carcinoma After Complete Resection. Journal of Clinical Endocrinology and Metabolism, 2015, 100, 841-849.	1.8	274
149	Large cell carcinoma of the lung: A tumor in search of an author. A clinically oriented critical reappraisal. Lung Cancer, 2015, 87, 226-231.	0.9	39
150	Identification of MicroRNAs Differentially Expressed in Lung Carcinoid Subtypes and Progression. Neuroendocrinology, 2015, 101, 246-255.	1.2	45
151	Morgana acts as an oncosuppressor in chronic myeloid leukemia. Blood, 2015, 125, 2245-2253.	0.6	19
152	Classification of lung neuroendocrine tumors: lights and shadows. Endocrine, 2015, 50, 315-319.	1.1	40
153	Pitfalls in the diagnosis of adrenocortical tumors: a lesson from 300 consultation cases. Human Pathology, 2015, 46, 1799-1807.	1.1	44
154	Expression Analysis of Genes Involved in DNA Repair or Synthesis in Mixed Neuroendocrine/Nonneuroendocrine Carcinomas. Neuroendocrinology, 2015, 101, 151-160.	1.2	25
155	RRM1 modulates mitotane activity in adrenal cancer cells interfering with its metabolization. Molecular and Cellular Endocrinology, 2015, 401, 105-110.	1.6	23
156	mTOR pathway activation in multiple myeloma cell lines and primary tumour cells: pomalidomide enhances cytoplasmic-nuclear shuttling of mTOR protein. Oncoscience, 2015, 2, 382-394.	0.9	10
157	Non genomic loss of function of tumor suppressors in CML: BCR-ABL promotes llºBl± mediated p53 nuclear exclusion. Oncotarget, 2015, 6, 25217-25225.	0.8	16
158	CAVEOLIN-1 expression in brain metastasis from lung cancer predicts worse outcome and radioresistance, irrespective of tumor histotype. Oncotarget, 2015, 6, 29626-29636.	0.8	16
159	CYP2W1 Is Highly Expressed in Adrenal Glands and Is Positively Associated with the Response to Mitotane in Adrenocortical Carcinoma. PLoS ONE, 2014, 9, e105855.	1.1	41
160	Comparative diagnostic and prognostic performances of the hematoxylin-eosin and phospho-histone H3 mitotic count and Ki-67 index in adrenocortical carcinoma. Modern Pathology, 2014, 27, 1246-1254.	2.9	67
161	RFamide Peptides 43RFa and 26RFa Both Promote Survival of Pancreatic \hat{l}^2 -Cells and Human Pancreatic Islets but Exert Opposite Effects on Insulin Secretion. Diabetes, 2014, 63, 2380-2393.	0.3	44
162	Napsin-A, TTF-1, EGFR, and ALK Status Determination in Lung Primary and Metastatic Mucin-Producing Adenocarcinomas. International Journal of Surgical Pathology, 2014, 22, 401-407.	0.4	14

#	Article	IF	Citations
163	Bevacizumab plus octreotide and metronomic capecitabine in patients with metastatic well-to-moderately differentiated neuroendocrine tumors: the xelbevoct study. BMC Cancer, 2014, 14, 184.	1.1	76
164	Impact of Non–Small-Cell Lung Cancer-Not Otherwise Specified Immunophenotyping on Treatment Outcome. Journal of Thoracic Oncology, 2014, 9, 1540-1546.	0.5	24
165	Ki-67 Antigen in Lung Neuroendocrine Tumors: Unraveling a Role in Clinical Practice. Journal of Thoracic Oncology, 2014, 9, 273-284.	0.5	162
166	Cytotoxic activity of gemcitabine, alone or in combination with mitotane, in adrenocortical carcinoma cell lines. Molecular and Cellular Endocrinology, 2014, 382, 1-7.	1.6	25
167	The Roles of Multiparametric Magnetic Resonance Imaging, PCA3 and Prostate Health Index—Which is the Best Predictor of Prostate Cancer after a Negative Biopsy?. Journal of Urology, 2014, 192, 60-66.	0.2	68
168	Pathology of the Adrenal Cortex: a Reappraisal of the Past 25ÂYears Focusing on Adrenal Cortical Tumors. Endocrine Pathology, 2014, 25, 35-48.	5.2	28
169	Prognostic Role of Overt Hypercortisolism in Completely Operated Patients with Adrenocortical Cancer. European Urology, 2014, 65, 832-838.	0.9	121
170	ELOVL5 Mutations Cause Spinocerebellar Ataxia 38. American Journal of Human Genetics, 2014, 95, 209-217.	2.6	107
171	Extrapulmonary neuroendocrine small and large cell carcinomas: a review of controversial diagnostic and therapeutic issues. Human Pathology, 2014, 45, 665-673.	1.1	27
172	MicroRNA expression patterns in adrenocortical carcinoma variants and clinical pathologic correlations. Human Pathology, 2014, 45, 1555-1562.	1.1	50
173	Histologic and genotypic re-evaluation of non-small cell lung cancer (NSCLC): A monocentric study Journal of Clinical Oncology, 2014, 32, e19083-e19083.	0.8	0
174	Next-generation sequencing in malignant pleural mesothelioma: A retrospective study Journal of Clinical Oncology, 2014, 32, 7530-7530.	0.8	0
175	Differential thymidylate synthase expression in lung cancer adenocarcinoma subtypes Journal of Clinical Oncology, 2014, 32, e18539-e18539.	0.8	0
176	Diagnostic and prognostic role of steroidogenic factor 1 in adrenocortical carcinoma: a validation study focusing on clinical and pathologic correlates. Human Pathology, 2013, 44, 822-828.	1.1	76
177	Ghrelin and Tumors. Endocrine Development, 2013, 25, 122-134.	1.3	14
178	Subtyping Non–Small Cell Lung Cancer. International Journal of Surgical Pathology, 2013, 21, 326-336.	0.4	35
179	The Reticulin Algorithm for Adrenocortical Tumor Diagnosis. American Journal of Surgical Pathology, 2013, 37, 1433-1440.	2.1	75
180	î"Np63 (p40) Distribution Inside Lung Cancer. International Journal of Surgical Pathology, 2013, 21, 229-239.	0.4	51

#	Article	IF	Citations
181	Human ASH-1 Promotes Neuroendocrine Differentiation in Androgen Deprivation Conditions and Interferes With Androgen Responsiveness in Prostate Cancer Cells. Prostate, 2013, 73, 1241-1249.	1.2	26
182	Current State-of-the-Art Therapy for Advanced Squamous Cell Lung Cancer. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2013, , 354-358.	1.8	9
183	Prognostic and predictive biomarkers in early stage non-small cell lung cancer: tumor based approaches including gene signatures. Translational Lung Cancer Research, 2013, 2, 372-81.	1.3	44
184	Ribonucleotide Reductase Large Subunit (<i>RRM1</i>) Gene Expression May Predict Efficacy of Adjuvant Mitotane in Adrenocortical Cancer. Clinical Cancer Research, 2012, 18, 3452-3461.	3.2	64
185	î"Np63 (p40) and Thyroid Transcription Factor-1 Immunoreactivity on Small Biopsies or Cellblocks for Typing Non-small Cell Lung Cancer: A Novel Two-Hit, Sparing-Material Approach. Journal of Thoracic Oncology, 2012, 7, 281-290.	0.5	126
186	Obestatin regulates adipocyte function and protects against dietâ€induced insulin resistance and inflammation. FASEB Journal, 2012, 26, 3393-3411.	0.2	79
187	The challenge of NSCLC diagnosis and predictive analysis on small samples. Practical approach of a working group. Lung Cancer, 2012, 76, 1-18.	0.9	206
188	Surgical margin status of specimen and oncological outcomes after laparoscopic radical prostatectomy: experience after 400 procedures. World Journal of Urology, 2012, 30, 245-250.	1.2	11
189	Heterogeneity of Large Cell Carcinoma of the Lung. American Journal of Clinical Pathology, 2011, 136, 773-782.	0.4	48
190	Oncocytic Adrenocortical Tumors. American Journal of Surgical Pathology, 2011, 35, 1882-1893.	2.1	52
191	The pathological diagnosis of neuroendocrine tumors: common questions and tentative answers. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2011, 458, 393-402.	1.4	27
192	The Weiss Score and Beyond—Histopathology for Adrenocortical Carcinoma. Hormones and Cancer, 2011, 2, 333-340.	4.9	91
193	Immunohistochemical subtyping of nonsmall cell lung cancer not otherwise specified in fineâ€needle aspiration cytology. Cancer, 2011, 117, 3416-3423.	2.0	124
194	Adrenocortical Tumors With Myxoid Features: A Distinct Morphologic and Phenotypical Variant Exhibiting Malignant Behavior. American Journal of Surgical Pathology, 2010, 34, 973-983.	2.1	81
195	Poorly Differentiated Thyroid Carcinoma: 5ÂYears after the 2004 WHO Classification of Endocrine Tumours. Endocrine Pathology, 2010, 21, 1-6.	5.2	56
196	The prognostic role of immunohistochemical chromogranin a expression in prostate cancer patients is significantly modified by androgenâ€deprivation therapy. Prostate, 2010, 70, 718-726.	1.2	49
197	Mammalian target of rapamycin signaling activation patterns in neuroendocrine tumors of the lung. Endocrine-Related Cancer, 2010, 17, 977-987.	1.6	84
198	Unacylated ghrelin and obestatin increase islet cell mass and prevent diabetes in streptozotocin-treated newborn rats. Journal of Molecular Endocrinology, 2010, 45, 9-17.	1.1	78

#	Article	IF	CITATIONS
199	Gemcitabine plus metronomic 5-fluorouracil or capecitabine as a second-/third-line chemotherapy in advanced adrenocortical carcinoma: a multicenter phase II study. Endocrine-Related Cancer, 2010, 17, 445-453.	1.6	138
200	Poorly differentiated carcinoma of the thyroid: validation of the Turin proposal and analysis of IMP3 expression. Modern Pathology, 2010, 23, 1269-1278.	2.9	145
201	Neuroendocrine differentiation in breast cancer: established facts and unresolved problems. Seminars in Diagnostic Pathology, 2010, 27, 69-76.	1.0	108
202	Neuroendocrine Differentiation Patterns in Various Organs (Including Lung, Breast, Skin and) Tj ETQq0 0 0 rgBT	Overlock :	10 Tf 50 622
203	Review Article: A Reevaluation of the Clinical Significance of Histological Subtyping of Non—Small-Cell Lung Carcinoma: Diagnostic Algorithms in the Era of Personalized Treatments. International Journal of Surgical Pathology, 2009, 17, 206-218.	0.4	84
204	Morphology and a Limited Number of Immunohistochemical Markers May Efficiently Subtype Non–Small-Cell Lung Cancer. Journal of Clinical Oncology, 2009, 27, e141-e142.	0.8	41
205	ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: Towards a Standardized Approach to the Diagnosis of Gastroenteropancreatic Neuroendocrine Tumors and Their Prognostic Stratification. Neuroendocrinology, 2009, 90, 162-166.	1.2	313
206	Differential Thymidylate Synthase Expression in Different Variants of Large-Cell Carcinoma of the Lung. Clinical Cancer Research, 2009, 15, 7547-7552.	3.2	68
207	Continuous 5-fluorouracil infusion plus long acting octreotide in advanced well-differentiated neuroendocrine carcinomas. A phase II trial of the Piemonte Oncology Network. BMC Cancer, 2009, 9, 388.	1.1	62
208	Obestatin in human neuroendocrine tissues and tumours: expression and effect on tumour growth. Journal of Pathology, 2009, 218, 458-466.	2.1	42
209	Clinicopathological study of a series of 92 adrenocortical carcinomas: from a proposal of simplified diagnostic algorithm to prognostic stratification. Histopathology, 2009, 55, 535-543.	1.6	110
210	Desmocollin-3: a new marker of squamous differentiation in undifferentiated large-cell carcinoma of the lung. Modern Pathology, 2009, 22, 709-717.	2.9	91
211	RAS Mutations Are the Predominant Molecular Alteration in Poorly Differentiated Thyroid Carcinomas and Bear Prognostic Impact. Journal of Clinical Endocrinology and Metabolism, 2009, 94, 4735-4741.	1.8	181
212	Poorly Differentiated Carcinoma of the Thyroid Gland., 2009, 14, 219-223.		4
213	A Practical Diagnostic Approach to Solid/Trabecular Nodules in the Thyroid. Endocrine Pathology, 2008, 19, 75-81.	5. 2	20
214	Diagnostic Controversies in Vascular Proliferations of the Thyroid Gland. Endocrine Pathology, 2008, 19, 175-183.	5.2	30
215	Poorly Differentiated Thyroid Carcinoma: Diagnostic Features and Controversial Issues. Endocrine Pathology, 2008, 19, 150-155.	5.2	62
216	Human ASH1 expression in prostate cancer with neuroendocrine differentiation. Modern Pathology, 2008, 21, 700-707.	2.9	51

#	Article	IF	CITATIONS
217	Galectin-3-expression analysis in the surgical selection of follicular thyroid nodules with indeterminate fine-needle aspiration cytology: a prospective multicentre study. Lancet Oncology, The, 2008, 9, 543-549.	5.1	284
218	Thymidylate Synthase Expression in Gastroenteropancreatic and Pulmonary Neuroendocrine Tumors. Clinical Cancer Research, 2008, 14, 1059-1064.	3.2	81
219	Obestatin Promotes Survival of Pancreatic Â-Cells and Human Islets and Induces Expression of Genes Involved in the Regulation of Â-Cell Mass and Function. Diabetes, 2008, 57, 967-979.	0.3	173
220	Emerging drugs for adrenocortical carcinoma. Expert Opinion on Emerging Drugs, 2008, 13, 497-509.	1.0	29
221	Hyalinizing Trabecular Tumors of the Thyroid Gland are Almost all Benign. American Journal of Surgical Pathology, 2008, 32, 1877-1889.	2.1	105
222	Poorly Differentiated Thyroid Carcinoma: The Turin Proposal for the Use of Uniform Diagnostic Criteria and an Algorithmic Diagnostic Approach. American Journal of Surgical Pathology, 2007, 31, 1256-1264.	2.1	521
223	Cell Membrane Reactivity of MIB-1 Antibody to Ki67 in Human Tumors: Fact or Artifact?. Applied Immunohistochemistry and Molecular Morphology, 2007, 15, 220-223.	0.6	74
224	Brain–gut communication: cortistatin, somatostatin and ghrelin. Trends in Endocrinology and Metabolism, 2007, 18, 246-251.	3.1	42
225	Adjuvant Mitotane Treatment for Adrenocortical Carcinoma. New England Journal of Medicine, 2007, 356, 2372-2380.	13.9	679
226	Chromogranin A Expression in Patients With Hormone Na \tilde{A} -ve Prostate Cancer Predicts the Development of Hormone Refractory Disease. Journal of Urology, 2007, 178, 838-843.	0.2	86
227	Somatostatin receptor type 2A immunohistochemistry in neuroendocrine tumors: a proposal of scoring system correlated with somatostatin receptor scintigraphy. Modern Pathology, 2007, 20, 1172-1182.	2.9	266
228	Neuro-endocrine tumours of the lung. A review of relevant pathological and molecular data. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2007, 451, 51-59.	1.4	43
229	Goblet cell carcinoids and other mixed neuroendocrine/nonneuroendocrine neoplasms. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2007, 451, 61-69.	1.4	25
230	Basaloid adenocarcinoma. A new variant of pulmonary adenocarcinoma. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2007, 451, 729-736.	1.4	12
231	Papillary thyroid carcinoma presenting as a solitary soft tissue arm metastasis in an elderly hyperthyroid patient. Case report and review of the literature. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2006, 448, 857-861.	1.4	31
232	The grey zone between pure (neuro)endocrine and non-(neuro)endocrine tumours: a comment on concepts and classification of mixed exocrine–endocrine neoplasms. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2006, 449, 499-506.	1.4	97
233	Squamous cell carcinoma of the lung compared with other histotypes shows higher messenger RNA and protein levels for thymidylate synthase. Cancer, 2006, 107, 1589-1596.	2.0	364
234	Galectin-3 and Ki-67 Expression in Multiglandular Parathyroid Lesions. American Journal of Clinical Pathology, 2006, 126, 59-66.	0.4	27

#	Article	IF	Citations
235	Cathepsin K Is Selectively Expressed in the Stroma of Lung Adenocarcinoma but Not in Bronchioloalveolar Carcinoma. American Journal of Clinical Pathology, 2006, 125, 847-854.	0.4	44
236	Bone Sialoprotein Is Predictive of Bone Metastases in Resectable Non–Small-Cell Lung Cancer: A Retrospective Case-Control Study. Journal of Clinical Oncology, 2006, 24, 4818-4824.	0.8	69
237	Cathepsin K is selectively expressed in the stroma of lung adenocarcinoma but not in bronchioloalveolar carcinoma. A useful marker of invasive growth. American Journal of Clinical Pathology, 2006, 125, 847-54.	0.4	21
238	Galectin-3 and HBME-1 expression in well-differentiated thyroid tumors with follicular architecture of uncertain malignant potential. Modern Pathology, 2005, 18, 541-546.	2.9	131
239	Expression of cortistatin and MrgX2, a specific cortistatin receptor, in human neuroendocrine tissues and related tumours. Journal of Pathology, 2005, 207, 336-345.	2.1	39
240	Galectin-3 expression in parathyroid carcinoma: immunohistochemical study of 26 cases. Human Pathology, 2005, 36, 908-914.	1.1	71
241	Immunohistochemical study of neuroendocrine differentiation in primary glandular lesions and tumors of the urinary bladder., 2005, 27, 218-24.		6
242	Ghrelin and Tumors. , 2004, , 143-164.		1
243	Expression of ghrelin and biological activity of specific receptors for ghrelin and des-acyl ghrelin in human prostate neoplasms and related cell lines. European Journal of Endocrinology, 2004, 150, 173-184.	1.9	181
244	Somatostatin Receptors and Their Interest in Diagnostic Pathology. Endocrine Pathology, 2004, 15, 275-292.	5.2	43
245	Prognostic Factors of Clinical Interest in Poorly Differentiated Carcinomas of the Thyroid. Endocrine Pathology, 2004, 15, 313-318.	5.2	29
246	Confocal microscope analysis and tridimensional reconstruction of papillary thyroid carcinoma nuclei. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2004, 444, 350-355.	1.4	29
247	Diagnostic role of galectin-3 in follicular thyroid tumors. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2004, 444, 309-312.	1.4	33
248	Myxoid adrenocortical adenoma with a pseudoglandular pattern. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2004, 445, 414-418.	1.4	18
249	Galectin-3 and HBME-1 expression in oncocytic cell tumors of the thyroid. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2004, 445, 183-8.	1.4	48
250	Poorly differentiated carcinomas of the thyroid with trabecular, insular, and solid patterns. Cancer, 2004, 100, 950-957.	2.0	198
251	Targeting the Ghrelin Receptor: Orally Active GHS and Cortistatin Analogs. Endocrine, 2003, 22, 13-18.	2.2	20
252	Ghrelin and the Endocrine Pancreas. Endocrine, 2003, 22, 19-24.	2.2	46

#	Article	IF	Citations
253	Oxyphilic and non-oxyphilic thyroid carcinoma cell lines differ in expressing apoptosis-related genes. Journal of Endocrinological Investigation, 2003, 26, 660-667.	1.8	10
254	Ghrelin in Fetal Thyroid and Follicular Tumors and Cell Lines. American Journal of Pathology, 2003, 162, 645-654.	1.9	118
255	Methodological Considerations Regarding the Use of Galectin-3 Expression Analysis in Preoperative Evaluation of Thyroid Nodules. Journal of Clinical Endocrinology and Metabolism, 2003, 88, 950-950.	1.8	22
256	Merkel Cell Carcinomas: Expression of S-Phase Kinase-Associated Protein 2 (Skp2), p27, and Proliferation Markers. Endocrine Pathology, 2003, 14, 221-230.	5.2	2
257	Glutathione S-transferase T1 and M1 polymorphisms and risk of thyroid neoplasms. Archive of Oncology, 2003, 11, 185-185.	0.2	0
258	Expression of Ghrelin and of the GH Secretagogue Receptor by Pancreatic Islet Cells and Related Endocrine Tumors. Journal of Clinical Endocrinology and Metabolism, 2002, 87, 1300-1308.	1.8	306
259	Role of galectin-3 immunodetection in the cytological diagnosis of thyroid cystic papillary carcinoma. European Journal of Endocrinology, 2002, 147, 515-521.	1.9	45
260	Endocrine Activities of Cortistatin-14 and Its Interaction with GHRH and Ghrelin in Humans. Journal of Clinical Endocrinology and Metabolism, 2002, 87, 3783-3790.	1.8	72
261	The Antiproliferative Effect of Synthetic Peptidyl GH Secretagogues in Human CALU-1 Lung Carcinoma Cells. Endocrinology, 2002, 143, 484-491.	1.4	103
262	RET Activation and Clinicopathologic Features in Poorly Differentiated Thyroid Tumors. Journal of Clinical Endocrinology and Metabolism, 2002, 87, 370-379.	1.8	99
263	Ghrelin Expression in Fetal, Infant, and Adult Human Lung. Journal of Histochemistry and Cytochemistry, 2002, 50, 1013-1021.	1.3	123
264	Ghrelin Secretion Is Inhibited by Either Somatostatin or Cortistatin in Humans. Journal of Clinical Endocrinology and Metabolism, 2002, 87, 4829-4832.	1.8	152
265	Expression of thyroid transcription factor-1 in the spectrum of neuroendocrine cell lung proliferations with special interest in carcinoids. Human Pathology, 2002, 33, 175-182.	1.1	176
266	Neuroendocrine and peripheral activities of ghrelin: implications in metabolism and obesity. European Journal of Pharmacology, 2002, 440, 235-254.	1.7	324
267	Steroid hormone receptor in pleural solitary fibrous tumours and CD34+ progenitor stromal cells. Journal of Pathology, 2002, 198, 252-257.	2.1	45
268	Application of an immunodiagnostic method for improving preoperative diagnosis of nodular thyroid lesions. Lancet, The, 2001, 357, 1644-1650.	6.3	379
269	Ghrelin, a Natural GH Secretagogue Produced by the Stomach, Induces Hyperglycemia and Reduces Insulin Secretion in Humans. Journal of Clinical Endocrinology and Metabolism, 2001, 86, 5083-5083.	1.8	603
270	Ghrelin-Producing Endocrine Tumors of the Stomach and Intestine. Journal of Clinical Endocrinology and Metabolism, 2001, 86, 5052-5059.	1.8	121

#	Article	IF	CITATIONS
271	34Î ² E12 Cytokeratin Immunodetection in the Differential Diagnosis of Neuroendocrine Carcinomas of the Breast. Applied Immunohistochemistry and Molecular Morphology, 2001, 9, 229-233.	0.6	7
272	Title is missing!. Applied Immunohistochemistry & Molecular Morphology, 2001, 9, 229-233.	2.0	7
273	Expression of somatostatin receptor types 2, 3 and 5 in biopsies and surgical specimens of human lung tumours. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2001, 439, 787-797.	1.4	105
274	Immunohistochemical detection of somatostatin receptor types 1-5 in medullary carcinoma of the thyroid. Clinical Endocrinology, 2001, 54, 641-649.	1.2	122
275	Somatostatin Octapeptides (Lanreotide, Octreotide, Vapreotide, and Their Analogs) Share the Growth Hormone–Releasing Peptide Receptor in the Human Pituitary Gland. Endocrine, 2001, 14, 029-033.	2.2	20
276	Hexarelin Protects H9c2 Cardiomyocytes from Doxorubicin-Induced Cell Death. Endocrine, 2001, 14, 113-119.	2.2	39
277	Classic and Recent Special Stains Used in Differential Diagnosis of Endocrine Tumors. Endocrine Pathology, 2001, 12, 379-388.	5.2	7
278	Frequent RET Rearrangements in Thyroid Papillary Microcarcinoma Detected by Interphase Fluorescence In Situ Hybridization. Laboratory Investigation, 2001, 81, 1639-1645.	1.7	48
279	Expression of Apocrine Differentiation Markers in Neuroendocrine Breast Carcinomas of Aged Women. Modern Pathology, 2001, 14, 768-776.	2.9	112
280	Effects of Octreotide Treatment on the Proliferation and Apoptotic Index of GH-Secreting Pituitary Adenomas. Journal of Clinical Endocrinology and Metabolism, 2001, 86, 5194-5200.	1.8	62
281	Endocrine Activities of Ghrelin, a Natural Growth Hormone Secretagogue (GHS), in Humans: Comparison and Interactions with Hexarelin, a Nonnatural Peptidyl GHS, and GH-Releasing Hormone1. Journal of Clinical Endocrinology and Metabolism, 2001, 86, 1169-1174.	1.8	428
282	Identification, Characterization, and Biological Activity of Specific Receptors for Natural (Ghrelin) and Synthetic Growth Hormone Secretagogues and Analogs in Human Breast Carcinomas and Cell Lines 1. Journal of Clinical Endocrinology and Metabolism, 2001, 86, 1738-1745.	1.8	277
283	Large Cell Neuroendocrine Carcinoma of the Gallbladder. American Journal of Surgical Pathology, 2000, 24, 1424-1428.	2.1	76
284	RET/PTC Activation in Hyalinizing Trabecular Tumors of the Thyroid. American Journal of Surgical Pathology, 2000, 24, 1615-1621.	2.1	152
285	Thyroglobulin mRNA expression helps to distinguish anaplastic carcinoma from angiosarcoma of the thyroid. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2000, 437, 635-642.	1.4	34
286	AgNOR quantity as a prognostic tool in hyperplastic and neoplastic parathyroid glands. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2000, 437, 298-303.	1.4	16
287	Growth Hormone Secretagogue Binding Sites in Peripheral Human Tissues1. Journal of Clinical Endocrinology and Metabolism, 2000, 85, 3803-3807.	1.8	369
288	Correlative Immunohistochemical and Reverse Transcriptase Polymerase Chain Reaction Analysis of Somatostatin Receptor Type 2 in Neuroendocrine Tumors of the Lung. Diagnostic Molecular Pathology, 2000, 9, 47-57.	2.1	52

#	Article	IF	CITATIONS
289	Quantitation of somatostatin receptor type 2 in neuroendocrine (merkel cell) carcinoma of the skin by competitive RT-PCR. Endocrine Pathology, 1999, 10, 37-46.	5.2	16
290	Proliferative activity of oxyphilic (Hurthle) cells in reactive and neoplastic thyroid lersions. Endocrine Pathology, 1999, 10, 173-179.	5.2	2
291	Chromogranin A gene expression in non-small cell lung carcinomas. , 1998, 186, 151-156.		44
292	Diagnostic cytological features of neuroendocrine differentiated carcinoma of the breast. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 1998, 433, 217-222.	1.4	36
293	Pancreatic Oncocytic Endocrine Tumors. Acta Cytologica, 1996, 40, 742-746.	0.7	26
294	Oxytocin and oxytocin-analogue F314 inhibit cell proliferation and tumor growth of rat and mouse mammary carcinomas., 1996, 66, 817-820.		44
295	Papillary and follicular thyroid carcinomas with an insular component. Cancer, 1994, 74, 2599-2600.	2.0	39
296	Detection of human androgen receptor mRNA in hepatocellular carcinoma by <i>in situ</i> hybridisation. Liver, 1994, 14, 213-219.	0.1	18
297	Apocrine carcinoma of the skin. A clinicopathologic, Immunocytochemical, and ultrastructural study. Cancer, 1993, 71, 375-381.	2.0	118
298	Intriguing Case: Argyrophilic Neuroendocrine Carcinoma of the Male Breast. Ultrastructural Pathology, 1993, 17, 115-120.	0.4	18
299	Gastric carcinoids and their precursor lesions. A histologic and immunohistochemical study of 23 cases. Cancer, 1991, 67, 663-672.	2.0	161
300	Cytologic Features of Poorly Differentiated †Insular†Carcinoma of the Thyroid, as Revealed by Fine-Needle Aspiration Biopsy. American Journal of Clinical Pathology, 1990, 94, 687-692.	0.4	89
301	Ultrastructural Features of Neuroendocrine Differentiated Carcinomas of the Breast. Ultrastructural Pathology, 1990, 14, 321-334.	0.4	37
302	A combined glucagonoma and VIPoma syndrome: First pathologic and clinical report. Cancer, 1988, 62, 2576-2579.	2.0	7
303	The Antiproliferative Effect of Synthetic Peptidyl GH Secretagogues in Human CALU-1 Lung Carcinoma Cells. , 0, .		40